Article
Biochemistry & Molecular Biology
Ana Bocanegra, Gonzalo Fernandez-Hinojal, Daniel Ajona, Ester Blanco, Miren Zuazo, Maider Garnica, Luisa Chocarro, Elvira Alfaro-Arnedo, Sergio Pineiro-Hermida, Pilar Morente, Leticia Fernandez, Ana Remirez, Miriam Echaide, Maite Martinez-Aguillo, Idoia Morilla, Beatriz Tavira, Alejandra Roncero, Carolina Gotera, Alfonso Ventura, Nerea Recalde, Jose G. Pichel, Juan Jose Lasarte, Luis Montuenga, Ruth Vera, Ruben Pio, David Escors, Grazyna Kochan
Summary: Recent studies show that baseline functional immunity is crucial for the success of immune checkpoint blockade therapies. In this study, high-dimensional systemic immune profiling was performed on non-small-cell lung cancer patients undergoing PD-L1/PD-1 blockade immunotherapy. Responders had a higher diversity of myeloid phenotypes in their peripheral blood. A diversity index was defined as a potential biomarker of response. Fractalkine (FKN), a chemokine linked to immune chemotaxis and adhesion, was identified as a biomarker of response and correlated with myeloid cell diversity. FKN inhibited lung adenocarcinoma growth in both human and mouse models through the involvement of systemic effector NK cells and increased tumor immune infiltration. FKN also sensitized mouse lung cancer models resistant to anti-PD-1 treatment to immunotherapy, indicating its potential therapeutic use in combination with immunotherapy.
Article
Multidisciplinary Sciences
Changsheng Huang, Shengxiang Ren, Yaqi Chen, Anyi Liu, Qi Wu, Tao Jiang, Panjing Lv, Da Song, Fuqing Hu, Jingqing Lan, Li Sun, Xue Zheng, Xuelai Luo, Qian Chu, Keyi Jia, Yan Li, Jun Wang, Caicun Zou, Junbo Hu, Guihua Wang
Summary: This research discovered that PD-L1 K162 was methylated by SETD7 and demethylated by LSD2. Additionally, PD-L1 K162 methylation controlled the PD1/PD-L1 interaction and significantly enhanced the suppression of T cell activity in controlling cancer immune surveillance. The study demonstrated that PD-L1 hypermethylation was the key mechanism for anti-PD-L1 therapy resistance, identified PD-L1 K162 methylation as a negative predictive marker for anti-PD-1 treatment in patients with non-small cell lung cancer, and showed that the PD-L1 K162 methylation:PD-L1 ratio was a more accurate biomarker for predicting anti-PD-(L)1 therapy sensitivity.
Article
Immunology
Kai Liu, Hui-Huang Huang, Tao Yang, Yan-Mei Jiao, Chao Zhang, Jin-Wen Song, Ji-Yuan Zhang, Chun-Bao Zhou, Jin-Hong Yuan, Wen-Jing Cao, Xiu-Ying Mu, Ming-Ju Zhou, Hua-Jie Li, Ming Shi, Ruonan Xu, Fu-Sheng Wang
Summary: Neutrophils in HIV-1 infection undergo aging and over-aggregation, leading to T cell dysfunction. Dampening neutrophil aging may provide a novel approach to recover T cell dysfunction in patients with HIV-1 infection. So it's important to study the dynamics of neutrophil aging and its relationship with T cell exhaustion.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Zhang-Wei Hu, Wei Sun, Yi-Hui Wen, Ren-Qiang Ma, Lin Chen, Wen-Qing Chen, Wen-Bin Lei, Wei-Ping Wen
Summary: CD69 and SBK1 are potential biomarkers to predict response to cancer immunotherapy, guiding treatment decisions for precision therapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Cell Biology
Olga Yajuk, Maya Baron, Sapir Toker, Tamir Zelter, Tanya Fainsod-Levi, Zvi Granot
Summary: The PD-L1/PD-1 axis plays a crucial role in mediating immune tolerance and promoting tumor growth by inhibiting anti-tumor immunity. Blocking this axis has been shown to help maintain the anti-tumor functions of the adaptive immune system. Neutrophils consist of distinct subpopulations with either pro- or anti-tumor properties, and PD-L1 expression in neutrophils can either promote or inhibit tumor growth.
Review
Pharmacology & Pharmacy
Mu-Yang Huang, Xiao-Ming Jiang, Bing-Lin Wang, Yang Sun, Jin-Jian Lu
Summary: While PD-1/PD-L1 immunotherapy has been approved for treating NSCLC, only a modest population of patients benefit from it, with some experiencing relapse and progression. Combination therapy emerges as an effective way to broaden beneficiaries and overcome resistance, although challenges need to be addressed.
PHARMACOLOGY & THERAPEUTICS
(2021)
Review
Oncology
Durgesh Wankhede, Paul Hofman, Sandeep Grover
Summary: The study suggests that tumors with PD-L1 expression below 1% can also benefit from PD-1/PD-L1 inhibitor-chemotherapy regimens, leading to improved overall survival and progression-free survival in advanced NSCLC patients.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Immunology
Yanping Li, Tianhong Chen, Tian Yi Nie, Juyuan Han, Yunyan He, Xingxing Tang, Li Zhang
Summary: Immune checkpoint inhibitors (ICIs) effectively activate the anti-tumor immune function of T cells in non-small cell lung cancer patients by targeting the negative regulatory pathway of T cells. However, Hyperprogressive Disease, characterized by accelerated tumor growth and poor prognosis, poses a challenge to this promising immunotherapy. This review provides a comprehensive overview of Hyperprogressive Disease in ICIs-based immunotherapy for non-small cell lung cancer, including its definition, biomarkers, mechanisms, and treatment.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Pharmacology & Pharmacy
Man Wang, Lijie Zhu, Xiaoxu Yang, Jiahui Li, Yu'e Liu, Ying Tang
Summary: Lung cancer, the most deadly malignant tumor, has shown benefits from immunotherapy, particularly immune checkpoint inhibitors. However, cancer patients often develop adaptive immune resistance, resulting in poor prognosis. The tumor microenvironment plays a critical role in acquired adaptive immune resistance in lung cancer.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Enrico Munari, Francesca R. Mariotti, Linda Quatrini, Pietro Bertoglio, Nicola Tumino, Paola Vacca, Albino Eccher, Francesco Ciompi, Matteo Brunelli, Guido Martignoni, Giuseppe Bogina, Lorenzo Moretta
Summary: Immune evasion is a crucial strategy adopted by tumor cells to promote survival and metastasis, with PD-1 playing a major role in inhibiting immune responses. Targeting the PD-1/PD-L1 axis has been a significant breakthrough in cancer treatment, representing unprecedented success in various cancer types. Further research on mechanisms regulating PD-1 expression and signaling in tumors is needed to improve therapeutic efficacy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Laure Chardin, Alexandra Leary
Summary: Ovarian cancer is a highly lethal gynecologic malignancy with a high recurrence rate, despite many patients responding effectively to current treatments. In order to improve outcomes, further research into the immune microenvironment and the development of effective therapies are urgently needed.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Hui Yu, Ping Chen, Liangping Xia, Sha Fu, Chen Chen, Xuanye Zhang, Lina He, Bei Zhang, Yixin Zhou, Shaodong Hong
Summary: This study conducted an indirect comparison between ICI + chemo and beva + chemo in first-line treatment for non-squamous NSCLC. The results showed that ICI + chemo reduced the risk of disease progression and death compared with beva + chemo. Overall, ICI + chemo was found to be superior to beva + chemo in this setting.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Immunology
Mengke Niu, Yiming Liu, Ming Yi, Dechao Jiao, Kongming Wu
Summary: The immune checkpoint pathway involving PD-1 and PD-L1 plays a crucial role in inhibiting T-cell proliferation and function, affecting antitumor immune responses. Alternative forms of PD-1/PD-L1, such as sPD-1/sPD-L1 and exoPD-L1, have been detected in cancer patients and may have significant biological activities.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Ali Razaghi, Mickael Durand-Dubief, Nele Brusselaers, Mikael Bjornstedt
Summary: PD-1 and PD-L1 play crucial roles in immune regulation and can be targeted for cancer treatment. Blocking PD-1/PD-L1 can enhance tumor recognition by activated T cells and combining it with type I interferon (IFN) can further improve therapeutic efficacy.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Plant Sciences
Myong Hak Ri, Juan Ma, Xuejun Jin
Summary: This study reviews the pharmacological effects of natural products, raw extracts, and traditional medicines associated with the PD-1/PD-L1 axis in cancer immunotherapy, particularly focusing on PD-L1. It was found that several natural products and traditional medicines have diverse and multi-functional effects that can improve strategies for anti-PD-1/PD-L1 therapy, but further research and exploration are needed.
JOURNAL OF ETHNOPHARMACOLOGY
(2021)